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Egfl7 is an endothelial-specific gene which expression is deregulated in human cancers. We showed that Egfl7 promotes
tumor escape from immunity by downregulating the expression of leukocyte adhesion molecules in endothelial cells,
thus repressing immune cell extravasation into tumors.
The tumor blood vessel endothelium
forms an imperfectly tight barrier which
actively protects the tumor mass from the
immune system. Tumor escape from
immunity is achieved, in part, by the
downregulation of leukocyte adhesion
molecules normally expressed by activated
endothelial cells. This endothelium
anergy limits the adhesion and infiltration
of effector immune cells within the
tumor.
1-3 We found that Egfl7 induces
this mechanism in endothelial cells,
and thus promotes tumor escape from
the immune system.
4
Egfl7 (also named VE-statin) is a
secreted protein specifically expressed by
endothelial cells during embryogenesis.
5
Egfl7 represses smooth muscle cell migra-
tion, suggesting a role for this protein in
vascular maturation. Egfl7 is also an
endogenous repressor of endothelial elasto-
genesis via its interaction with lysyl
oxydases and repression of their catalytic
activity.
6 A few reports showed that egfl7 is
deregulated in human cancer; its expres-
sion is not anymore restricted to the
endothelium in human tumors, but is
also detected in cancer cells themselves.
Further, Egfl7 expression levels in human
hepatocarcinoma, glioma, and colon
cancer correlate with a higher tumor grade,
with a poorer prognosis and higher
metastatic scores,
7-9 suggesting that Egfl7
is associated with tumor progression.
In order to understand its role during
tumor growth and metastasis, we over-
expressed Egfl7 in breast cancer 4T1 and
lung adenocarcinoma LLC1 cells, and
analyzed the resulting effects in vitro and
in vivo. Overexpression of Egfl7 had no
effects on tumor cell proliferation, migra-
tion, or clone formation in vitro, suggest-
ing that the protein has no major effects
on tumor cells themselves. On the other
hand, when implanted in Balb/c or
C57Bl/6 mice, tumors expressing Egfl7
grew faster and induced a higher incidence
of lung metastasis than controls. Egfl7
increased the tumor vascular density,
endothelium permeability, necrosis, and
hypoxia. On the other hand, Egfl7 had no
effects on the Ki67 proliferation index of
tumor cells or on apoptosis.
More interestingly, when tumor cells
were implanted in immune-deficient
SCID-Bg mice, Egfl7 had no effects on
tumor growth and metastasis anymore,
suggesting that the effects of Egfl7 were
strictly dependent on the existence of
an intact immune system in the receiving
mice. Furthermore, control tumors grew
in SCID-Bg mice as fast as tumors
overexpressing Egfl7 grew in Balb/c mice,
suggesting that, in immunocompetent
mice, Egfl7 could create an immuno-
deficient environment within the tumor
which would favor its growth.
A detailed analysis of the morphology of
tumors grown in immunocompetent mice
revealed the presence of numerous indivi-
dualized cells in the blood vessels lumens
of tumors expressing Egfl7, while a small
number of such cells were infiltrated
within the tumor tissues. On the contrary,
most of these cells infiltrated the tissues
of control tumors and few were observed
in the blood vessels. In parallel, RNA
and protein arrays analyses showed that
IFNc expression was severely reduced in
tumors overexpressing Egfl7 when com-
pared with controls, suggesting that these
tumors were depleted of immune cells.
Immunostainings confirmed that T-lym-
phocytes had massively infiltrated control
tumors whereas tumors overexpressing
Egfl7 were much less infiltrated and most
T-lymphocytes were sequestered in the
blood vessels lumens (Fig. 1). This was
repeatedly observed with all immune cells
tested, namely CD4 and CD8 T-lympho-
cytes, B-lymphocytes, dendritic cells,
macrophages and NK cells, which were
down-represented in tumors overexpress-
ing Egfl7 when compared with control
tumors. This implied that Egfl7 affected
the infiltration of all types of immune
cells, with no particular specificity.
However, Egfl7 had no direct effects on
immune cells, as it was not able to decrease
the basal or induced proliferation of T
lymphocytes, nor the basal or induced
activation of T-lymphocytes, dendritic
cells, and NK cells. Second, the effects of
Egfl7 on immune cells were locally
confined to the tumors and not systemic
since the spleens of mice bearing control
or tumors expressing Egfl7 were equally
well populated.
From all these observations, it became
highly probable that Egfl7 affected the
extravasation of immune cells from the
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analysis of expression of leukocyte adhe-
sion molecules confirmed this hypothesis
and showed that endothelial cells from
tumors expressing Egfl7 expressed much
less ICAM-1, VCAM-1 and E-selectin
than controls (Fig. 1). We found that
expression of these adhesion molecules was
directly controlled by Egfl7 in endothelial
cells, as repressing endogenous egfl7 using
RNA interference promoted the expres-
sion of ICAM-1, VCAM-1 and E-selectin
and lymphocyte adhesion to these cells,
suggesting that Egfl7 is a constitutive
repressor of endothelial cell activation.
When switching to the human disease,
we noticed that in human breast cancer
tumors expressing high levels of Egfl7,
blood vessel endothelial cells expressed less
ICAM-1 and VCAM-1 than in tumors
expressing low levels of Egfl7. In addition,
there was a direct and inverse correlation
between the levels of expression of egfl7
and those of ifnc, these two points
suggesting that Egfl7 promotes tumor
escape from immunity in human cancer
as it does in mice.
Egfl7 is therefore an endogenous regu-
lator of endothelial cell activation which,
when expressed in a tumor context, favors
tumor growth by downregulating immune
cell extravasation. Tumor escape from
immunity mediated by the endothelium
is undoubtedly an interesting process to
consider for the design of therapeutic tools
aimed at preventing cancer progression
and, following our observations, Egfl7
represents a new target for interfering with
these processes. It is worth noting that
since Egfl7 maintains the normal endo-
thelium in a non-activated state, interfer-
ing with this property when targeting
Egfl7 might produce severe adverse side
effects in normal organs.
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Figure1. Control tumors (top) show a large infiltration of CD3ε
+ T-lymphocytes (brown) and
express high levels of ICAM-1 (green) and VCAM-1 (red). Tumors expressing Egfl7 (bottom) have a
reduced infiltration of T-lymphocytes which mainly remain in the blood circulation (arrows), blood
vessels express much less ICAM-1 and VCAM-1 (inserts).
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